Asymchem Laboratories Tian Jin Co Ltd (002821) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.026x

Based on the latest financial reports, Asymchem Laboratories Tian Jin Co Ltd (002821) has a cash flow conversion efficiency ratio of 0.026x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥449.89 Million ≈ $65.83 Million USD) by net assets (CN¥17.36 Billion ≈ $2.54 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Asymchem Laboratories Tian Jin Co Ltd balance sheet quality to measure how much of total assets are equity-financed.

Asymchem Laboratories Tian Jin Co Ltd - Cash Flow Conversion Efficiency Trend (2011–2025)

This chart illustrates how Asymchem Laboratories Tian Jin Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Asymchem Laboratories Tian Jin Co Ltd earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.

Asymchem Laboratories Tian Jin Co Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Asymchem Laboratories Tian Jin Co Ltd ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Compañía de Minas Buenaventura S.A.A
F:MBU
0.044x
BRENNTAG SE UNSP.ADR/020
F:BNRA
0.076x
Als Ltd
AU:ALQ
0.127x
EVONIK INDUST.(U.ARD)2
F:EVKA
0.075x
Shoprite Holdings Ltd
JSE:SHP
0.287x
Quinenco
SN:QUINENCO
0.092x
Hengyi Petrochemical Co Ltd
SHE:000703
0.025x
Evonik Industries AG
F:EVK
0.075x

Annual Cash Flow Conversion Efficiency for Asymchem Laboratories Tian Jin Co Ltd (2011–2025)

The table below shows the annual cash flow conversion efficiency of Asymchem Laboratories Tian Jin Co Ltd from 2011 to 2025. For the full company profile with market capitalisation and key ratios, see Asymchem Laboratories Tian Jin Co Ltd stock valuation.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 CN¥17.65 Billion
≈ $2.58 Billion
CN¥1.41 Billion
≈ $205.97 Million
0.080x +7.23%
2024-12-31 CN¥16.86 Billion
≈ $2.47 Billion
CN¥1.25 Billion
≈ $183.55 Million
0.074x -63.31%
2023-12-31 CN¥17.51 Billion
≈ $2.56 Billion
CN¥3.55 Billion
≈ $519.44 Million
0.203x -3.20%
2022-12-31 CN¥15.70 Billion
≈ $2.30 Billion
CN¥3.29 Billion
≈ $480.98 Million
0.209x +2233.93%
2021-12-31 CN¥12.61 Billion
≈ $1.85 Billion
CN¥113.15 Million
≈ $16.56 Million
0.009x -90.56%
2020-12-31 CN¥5.99 Billion
≈ $876.49 Million
CN¥569.29 Million
≈ $83.31 Million
0.095x -51.83%
2019-12-31 CN¥3.05 Billion
≈ $445.65 Million
CN¥600.87 Million
≈ $87.93 Million
0.197x +19.34%
2018-12-31 CN¥2.51 Billion
≈ $367.38 Million
CN¥415.06 Million
≈ $60.74 Million
0.165x +81.41%
2017-12-31 CN¥2.16 Billion
≈ $315.35 Million
CN¥196.40 Million
≈ $28.74 Million
0.091x -39.99%
2016-12-31 CN¥1.83 Billion
≈ $268.22 Million
CN¥278.36 Million
≈ $40.73 Million
0.152x -44.63%
2015-12-31 CN¥937.02 Million
≈ $137.12 Million
CN¥256.99 Million
≈ $37.61 Million
0.274x +69.50%
2014-12-31 CN¥785.17 Million
≈ $114.90 Million
CN¥127.05 Million
≈ $18.59 Million
0.162x +4.81%
2013-12-31 CN¥686.10 Million
≈ $100.40 Million
CN¥105.92 Million
≈ $15.50 Million
0.154x +173.00%
2012-12-31 CN¥608.06 Million
≈ $88.98 Million
CN¥34.38 Million
≈ $5.03 Million
0.057x +18.47%
2011-12-31 CN¥542.26 Million
≈ $79.35 Million
CN¥25.88 Million
≈ $3.79 Million
0.048x --

About Asymchem Laboratories Tian Jin Co Ltd

SHE:002821 China Biotechnology
Market Cap
$8.00 Billion
CN¥54.70 Billion CNY
Market Cap Rank
#2597 Global
#301 in China
Share Price
CN¥164.28
Change (1 day)
-3.08%
52-Week Range
CN¥89.50 - CN¥195.75
All Time High
CN¥358.21
About

Asymchem Laboratories (Tianjin) Co., Ltd. provides contract development and manufacturing organization (CDMO) solutions in Mainland China and internationally. It is involved in small molecule CDMO services for projects covering multiple major disease treatment areas, such as oncology, antiviral, anti-infective, cardiovascular, and diabetes; chemical macromolecule CDMO; biomacromolecule CDMO, incl… Read more